Christoph Herold

Title: Christoph Herold: Innovator in Gene Inhibition

Introduction

Christoph Herold is a distinguished inventor based in Erlangen, Germany, known for his groundbreaking work in the field of genetic research. With a focus on innovative compositions related to gene expression, Herold has contributed significantly to advancements in therapeutic applications.

Latest Patents

Herold holds a patent for "Compositions and methods for inhibiting expression of anti-apoptotic genes." This invention involves a double-stranded ribonucleic acid (dsRNA) designed to inhibit the expression of an anti-apoptotic gene. The dsRNA features a complementary RNA strand of fewer than 25 nucleotides which is substantially identical to a segment of an apoptotic gene, such as a Bcl gene. The patent also encompasses a pharmaceutical composition that includes the dsRNA, paired with a pharmaceutically acceptable carrier, aimed at treating diseases linked to the expression of anti-apoptotic genes.

Career Highlights

Christoph Herold is currently associated with Alnylam Europe AG, a leading firm in the realm of RNA interference and genetic therapies. His work has not only broadened the understanding of gene inhibition but has potential applications in developing treatments for various diseases.

Collaborations

Herold collaborates with notable colleagues such as Roland Kreutzer and Stefan Limmer. Together, they contribute to cutting-edge research and innovations within their field, enhancing the capabilities and offerings of Alnylam Europe AG.

Conclusion

With his innovative approach to gene inhibition, Christoph Herold stands out as a key figure in modern genetic research. His contributions continue to pave the way for new therapeutic options that could significantly impact the medical field, proving the value of innovation in addressing complex biological challenges.